4-(4-氯噻吩-2-基)噻唑-2-胺

4-(4-氯噻吩-2-基)噻唑-2-胺 - Names and Identifiers

Name	2-ThiazolaMine, 4-(4-chloro-2-thienyl)-
Synonyms	Avatrombopag Impurity 8 4-(4-Chloro-2-thienyl)-2-thiazolamine 2-ThiazolaMine, 4-(4-chloro-2-thienyl)- 4-(4-Chlorothiophen-2-yl)thiazol-2-amine 2-Amino-4-(4-chlorothiophen-2-yl)thiazole 4-(4-chlorothiophen-2-yl)-1,3-thiazol-2-amine 2-ThiazolaMine, 4-(4-chloro-2-thienyl)- 2-ThiazolaMine 2-ThiazolaMine, 4-(4-chloro-2-thienyl)- 2-ThiazolaMine, 4-(4-chloro-2-thienyl)-
CAS	570407-10-2
EINECS	1312995-182-4

4-(4-氯噻吩-2-基)噻唑-2-胺 - Physico-chemical Properties

Molecular Formula	C7H5ClN2S2
Molar Mass	216.71
Density	1.535±0.06 g/cm3(Predicted)
Boling Point	395.3±27.0 °C(Predicted)
pKa	3.47±0.10(Predicted)

4-(4-氯噻吩-2-基)噻唑-2-胺 - Reference Information

Application

4-(4-chloro-2-thienyl)-2-thiazolamide is an important intermediate in the production of the TPO-R agonist atorvastatin trombopag in thrombocytopenia. Atorvastatin is mainly used for chemotherapy-induced thrombocytopenia (CIT), thrombocytopenia associated with chronic liver disease in adults undergoing elective diagnostic procedures or surgery (CLDT).

intermediate atorvastatin trombopag

thrombocytopenia is a bleeding disorder with severe thrombocytopenia such as chronic liver disease (CLD), chronic primary immune thrombocytopenia (ITP) has a high rate of spontaneous bleeding, and can even be life-threatening in severe cases. Thrombocytopenia caused by tumor chemotherapy can reduce the efficacy of chemotherapy, which is a common dose-limiting toxicity of chemotherapy drugs. Platelet transfusion, glucocorticoid and the first generation of recombinant full-length thrombopoietin are the main treatments for clinically relevant diseases in China.
thrombopoietin receptor agonist (TPO-R agonist for short) is the conventional therapy for thrombocytopenia in Europe and America. AkaRx's atorvastatin trombopag tablets, a second-generation oral TPO-R agonist, stimulate the proliferation and differentiation of megakaryocytes in bone marrow progenitor cells, thereby increasing platelet production. In May 2018, atorvastatin and propofol were approved in the United States for thrombocytopenia in patients with chronic liver disease who were scheduled to undergo medical or dental treatment, the United States has approved a new drug application supplement for atorvastatin to treat patients with chronic immune thrombocytopenia (ITP) who do not respond adequately to previous treatment.

Last Update：2024-04-09 15:16:44